CRO/CMO Panel on the Relationships to Small or Virtual Biotech/ Biopharma
With the more recent consolidation trends in CRO/CMO (contract research and contract manufacturing) suppliers, the landscape is rapidly changing and so the relationships between the parties must adjust.
As CROs consolidate and the small specialty providers become absorbed inside the much bigger organizations, the question is whether they will be able to be as responsive to their startup/smaller/virtual biotech clients as they are to their big pharma clients.
If you are considering launching a biotech, seeking new sourcing resources, or want to better understand how to orchestrate one or more service providers to conduct critical and complicated R&D projects, please join us and actively participate in our dialogue.
We have gathered a cross-section of biopharma and CRO representatives that have a front seat and a vested interest in how this scenario will play out.
Talking Points Include:
- With these consolidation trends, will service, quality and pricing change? improve?
- How can a smaller or virtual biopharma firms get the same level of attention and high quality support as big pharma?
- Who do you turn to for complicated and challenging projects that cross areas of specialty?
- How do you handle tech transfer from one CRO to another?
- How do you learn about the various CRO service offerings and select the one(s) that best fit?
- What are your biggest frustrations and challenges? What are the solutions to make these complicated situations from both sides easier and more productive?
Panel organized and led by Shelley Amster:
- Jeffrey P Kiplinger, Ph.D., General Manager, Averica Discovery, V.P. of Science and Innovation, Neopharm Lab
- Michael G. Palfreyman, PhD, DSc, SVP Drug Development, Aminex Therapeutics, Inc. and Chief Scientific Office, Amorsa Therapeutics, Inc.
- Vipula Tailor, CEO and Founder, Azure8
- Paul Wengender, CEO, Crow's Nest Bio
Dr. Kiplinger has over 25 years of experience in the pharmaceutical industry, initially as a mass spectrometrist and analytical chemist at Pfizer and later as a strategic consultant to startup discovery organizations. He is founder and CEO of Averica Discovery Services, an analytics Contract Research Organization (CRO) in Boston. Averica was acquired by Neopharm Labs (Blainville, QC) in 2016, and Dr. Kiplinger serves as Neopharm’s Vice President of Science and Innovation as well as General Manager of Averica.
Dr. Kiplinger received his PhD in Organic Chemistry at Indiana University, and carried out postdoctoral research at the University of North Carolina and Ohio State University. In 1988 he joined Pfizer in Groton Connecticut, leaving in 1998 to found the Gilson CIDT technical center. After consulting with a number of pharmaceutical companies and entrepreneurs, he founded Averica in 2007. Dr. Kiplinger has published over 30 research papers, in addition to several articles on high-throughput technologies and laboratory form and function. He has a strong interest in science and entrepreneurship.
Michael G. Palfreyman, PhD, DSc, President, Palfreyman BioPharma Consulting is a seasoned leader in the biotechnology and pharmaceutical industries with over four decades’ experience in leadership positions. He specializes in leading and guiding life sciences companies regarding their R&D strategy, financing, BD&L activities and product development and is President, Palfreyman BioPharm Advisors, LLC. In this capacity, Michael serves as Chief Scientific Officer at Amorsa Therapeutics, Inc., and Chairman of the SAB at Aminex Therapeutics, Inc. In addition, he is a Director of Oculogics, Inc and a Member of the Patent Review Board, Forsyth Dental Institute. He also serves as Senior R&D Diligence at Torrey Pines Investment & at ChemRar; as well as Scientific Advisor for Mak Sciences, Inc. NeurAegis, Inc., NeuroNascent, Inc., and Jasco Pharmaceuticals, Inc.,
Michael is a Fellow of the American College of Neuropsychopharmacology and his passion lies in the CNS field where he has contributed to, and overseen several research programs in Psychiatric and Neurological Diseases. He has also lead R&D programs in Cardiovascular, Cancer, Infectious, Metabolic and Respiratory Disorders.
Michael has previously held several key roles from Chairman of the Board, President & CSO, SVP R&D, to Head of Biotechnology licensing, in successful Biotech and Pharmaceutical companies, such as Amakem, NV, Ophthakem, NV; Chemical Diversity, Inc, Vitruvean, LLC, EnVivo (Forum) Pharmaceuticals, Inc., NOVACE Corporation, Psychiatric Genomics, Inc., Scriptgen (Anadys) Pharmaceuticals, Inc., as well as Marion Merrell Dow Research Institute (now Sanofi) and Beecham Pharmaceuticals (now Glaxo Smith Kline).
Michael’s own research included discovery and development of a number of psychotherapeutic compounds for treatment of psychosis, depression, stroke, epilepsy, emesis, Parkinson’s, Alzheimer’s and Huntington’s diseases. Many of these compounds, including early work on cannabinoid derivatives have entered clinical development and a number have reached the marketplace. Michael is a co-inventor on 43 issued patents and co-author of more than 150 publications.
Michael holds a D.Sc. (1996) in rational design of CNS drugs; a Ph.D. (1970) degree in Neuroscience and Neuropharmacology, as well as a B.Pharm (Magna cum Laude, 1967 in Pharmacy), and MRPharmS (Pharmacy Practice, 1971), all from the University of Nottingham, UK.
$25/30/35 early bird/regular/at the door